All Work

Chris Lange

How ASCO Could Make or Break These 5 Cancer Drug Trials

The 2017 annual meeting of the American Society of Clinical Oncology (ASCO) has the potential to make or break companies, with winners walking away from this event with a nice gain and losers trying…

Chris Lange · 9 years ago

What to Watch For in the Bright Scholar IPO

Bright Scholar Education Holdings has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

Chris Lange · 9 years ago

Why Cisco Earnings Aren’t Good Enough For Investors

Cisco Systems, Inc. (NASDAQ: CSCO) reported its fiscal third-quarter financial results after the markets closed on Wednesday. The networking giant said that it had $0.60 in earnings per share (EPS) and $11.9 billion in…

Chris Lange · 9 years ago

What to Expect From Cisco Earnings

Cisco Systems is scheduled to report its fiscal third-quarter financial results after the markets close on Wednesday.

Chris Lange · 9 years ago

Why Syndax Shares Are Rallying

Syndax Pharmaceuticals has announced that Encore 601 has met the prespecified objective response threshold to advance into the second stage of the Phase 2 trial and will reopen enrollment immediately.

Chris Lange · 9 years ago

How Qualcomm Is Ramping Up Its Legal Battle With Apple

Apple said in April that it had suspended royalty payments to Qualcomm because the two companies had been unable to work out a deal. Apparently these two companies have been trying to reach an…

Chris Lange · 9 years ago

Urban Outfitters Dives Lower on Missed Earnings

Urban Outfitters, Inc. (NASDAQ: URBN) reported its fiscal first-quarter financial results after the markets closed on Tuesday. The company said that it had $0.10 in earnings per share (EPS) and $761 million in revenue,…

Chris Lange · 9 years ago

Tuesday’s Biggest Winners and Losers in the S&P 500

May 16, 2017: The S&P 500 closed relatively flat on the day at 2,400.58. Separately the DJIA closed at 20,978.21. The Nasdaq actually closed up 0.3% at 6,169.87, hitting another high in the session.

Chris Lange · 9 years ago

Why Akebia Shares Are Hitting New Highs

Akebia Therapeutics saw its shares hit a new 52-week high in Tuesday’s session following a key licensing agreement with Vifor Pharma.

Chris Lange · 9 years ago

10 Most Pirated Movies Last Week

Pirating movies is a major problem in the United States, costing studios millions of dollars in lost box office ticket sales. According to several film industry studies, illegal movie downloads could be costing the…

Chris Lange · 9 years ago

Monday’s Biggest Winners and Losers in the S&P 500

Monday was a very strong day for the markets, so far the best trading day in May. There were green arrows across the board with no sector or industry really dragging the market. The…

Chris Lange · 9 years ago